MISSISSAUGA, Ontario, March 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2025. Key highlights include: (CAD) Q4 2025 % Change vs. Q4 2024 FY 2025 % Change vs. FY 2024 Canadian Pharma Sales 8,792,653 +3 % 37,143,783 +13 % International Pharma Sales 601,387 +240 % 3,735,...
MISSISSAUGA, Ontario, March 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2025. Key highlights include: (CAD) Q4 2025 % Change vs. Q4 2024 FY 2025 % Change vs. FY 2024 Canadian Pharma Sales 8,792,653 +3 % 37,143,783 +13 % International Pharma Sales 601,387 +240 % 3,735,959 +302 % Legacy Business Sales 277,883 +278 % 2,172,241 +86 % Total Company Sales 9,671,923 +10 % 43,051,983 +23 % EBITDA1 2,528,561 +13 % 12,122,756 +30 % Net Income After Taxes (NIAT) 1,991,788 +23 % 9,012,232 +24 % Fully Diluted EPS 0.17 +25 % 0.78 +27 % Return on Average Equity for FY 2025 was 24% as compared to 21% for FY 2024 During FY 2025, repurchased for cancellation a total of 19,500 common shares under a Normal Course Issuer Bid (NCIB) Paid quarterly cash dividends of $0.05 per common share on March 14, 2025, June 13, 2025, September 15, 2025, and December 15, 2025 Increased quarterly dividend by 10% to $0.055 per common share - paid on March 13, 2026 Generated $2.4 million in sales in 2025 from international Tibelia ® (tibolone) assets acquired in 2024 (tibolone) assets acquired in 2024 Completed acquisition of Oral Science Inc., a Canadian owner and distributor of specialized dental hygiene and oral health products, as announced on March 2, 2026 “We finished 2025 with double-digit overall revenue growth in the fourth quarter with continued growth in our Canadian pharmaceutical business and sizable contributions from our international Tibelia® business and legacy business,” commented Mr. René Goehrum, President and CEO of BioSyent. “For the full year, we are proud to have delivered 23% total Company revenue growth while maintaining a healthy 21% NIAT margin. We continue to invest in our FeraMAX® and Tibella® / Tibelia® products which were significant drivers of revenue and profit growth both in Canada and internationally during the year. We also continued to i...